161 related articles for article (PubMed ID: 31474860)
1. Efficacy and Safety of Multiple Dosages of Fostamatinib in Adult Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Kang Y; Jiang X; Qin D; Wang L; Yang J; Wu A; Huang F; Ye Y; Wu J
Front Pharmacol; 2019; 10():897. PubMed ID: 31474860
[No Abstract] [Full Text] [Related]
2. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Weinblatt ME; Genovese MC; Ho M; Hollis S; Rosiak-Jedrychowicz K; Kavanaugh A; Millson DS; Leon G; Wang M; van der Heijde D
Arthritis Rheumatol; 2014 Dec; 66(12):3255-64. PubMed ID: 25223724
[TBL] [Abstract][Full Text] [Related]
3. Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials.
Kunwar S; Devkota AR; Ghimire DK
Rheumatol Int; 2016 Aug; 36(8):1077-87. PubMed ID: 27113955
[TBL] [Abstract][Full Text] [Related]
4. Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial.
Weinblatt ME; Kavanaugh A; Genovese MC; Jones DA; Musser TK; Grossbard EB; Magilavy DB
J Rheumatol; 2013 Apr; 40(4):369-78. PubMed ID: 23378467
[TBL] [Abstract][Full Text] [Related]
5. A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist.
Genovese MC; van der Heijde DM; Keystone EC; Spindler AJ; Benhamou C; Kavanaugh A; Fudman E; Lampl K; O'Brien C; Duffield EL; Poiley J; Weinblatt ME
J Rheumatol; 2014 Nov; 41(11):2120-8. PubMed ID: 25225285
[TBL] [Abstract][Full Text] [Related]
6. Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.
Scott DL
Drugs; 2011 Jun; 71(9):1121-32. PubMed ID: 21711059
[TBL] [Abstract][Full Text] [Related]
7. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
[TBL] [Abstract][Full Text] [Related]
8. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Ruiz Garcia V; Burls A; Cabello JB; Vela Casasempere P; Bort-Marti S; Bernal JA
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD007649. PubMed ID: 28884785
[TBL] [Abstract][Full Text] [Related]
9. OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy.
Taylor PC; Genovese MC; Greenwood M; Ho M; Nasonov E; Oemar B; Stoilov R; Vencovsky J; Weinblatt M
Ann Rheum Dis; 2015 Dec; 74(12):2123-9. PubMed ID: 25074688
[TBL] [Abstract][Full Text] [Related]
10. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Ruiz Garcia V; Jobanputra P; Burls A; Cabello JB; Gálvez Muñoz JG; Saiz Cuenca ES; Fry-Smith A
Cochrane Database Syst Rev; 2011 Feb; (2):CD007649. PubMed ID: 21328299
[TBL] [Abstract][Full Text] [Related]
11. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Ruiz Garcia V; Jobanputra P; Burls A; Cabello JB; Vela Casasempere P; Bort-Marti S; Kynaston-Pearson FJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD007649. PubMed ID: 25231904
[TBL] [Abstract][Full Text] [Related]
12. Neoplasm Risk in Patients With Rheumatoid Arthritis Treated With Fostamatinib: A Systematic Review and Meta-analysis.
Chen Y; Liu H; Tian Y; Luo Z; Yin G; Xie Q
Front Pharmacol; 2022; 13():768980. PubMed ID: 35308252
[No Abstract] [Full Text] [Related]
13. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
[TBL] [Abstract][Full Text] [Related]
14. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
Weinblatt ME; Kavanaugh A; Genovese MC; Musser TK; Grossbard EB; Magilavy DB
N Engl J Med; 2010 Sep; 363(14):1303-12. PubMed ID: 20879879
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab for treating rheumatoid arthritis.
Navarro-Sarabia F; Ariza-Ariza R; Hernandez-Cruz B; Villanueva I
Cochrane Database Syst Rev; 2005 Jul; (3):CD005113. PubMed ID: 16034967
[TBL] [Abstract][Full Text] [Related]
17. The Cardiovascular Risks of Fostamatinib in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Chen Y; Liu H; Huang Y; Lin S; Yin G; Xie Q
Front Pharmacol; 2021; 12():632551. PubMed ID: 34349639
[No Abstract] [Full Text] [Related]
18. A Meta-Analysis Evaluating the Effectiveness and Safety of Upadacitinib in Treating Rheumatoid Arthritis in Patients With Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs.
Panchal V; Vyas BH; Sivasubramanian BP; Panchal K; Patel H
Cureus; 2023 Jan; 15(1):e34384. PubMed ID: 36874682
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
[TBL] [Abstract][Full Text] [Related]
20. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Burmester GR; Blanco R; Charles-Schoeman C; Wollenhaupt J; Zerbini C; Benda B; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Soma K; Bradley J; Mebus C;
Lancet; 2013 Feb; 381(9865):451-60. PubMed ID: 23294500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
